(8S)-8-ETHYL-2,3-DIHYDRO-8-HYDROXY-15-((4-METHYL-1-PIPERAZINYL)METHYL)-11H-P-DIOXINO(2,3-G)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-9,12(8H,14H)-DIONE

Carcinoma, Small Cell

Astellas Pharma IncSmall moleculePhase 2Dormant

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

1 Active assets in the Carcinoma, Small Cell cohort.

Asset / Sponsor	Phase	Rating
Sagopilone Bayer	Phase 2	B
Romidepsin National Cancer Institute (NCI)	Phase 2	B
Arsenic Trioxide Emory University	Phase 2	B
Vosaroxin Sunesis Pharmaceuticals	Phase 2	B
bi 2536 Boehringer Ingelheim	Phase 2	B

View all 21 →

Same molecule, other indications

(8S)-8-ETHYL-2,3-DIHYDRO-8-HYDROXY-15-((4-METHYL-1-PIPERAZINYL)METHYL)-11H-P-DIOXINO(2,3-G)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-9,12(8H,14H)-DIONE is also rated in:

small cell lung carcinomaDormant

Indicative ·

57 / 100

View asset →

primary peritoneal carcinomaDormant

Indicative ·

57 / 100

View asset →

ovarian neoplasmDormant

CCC

Indicative ·

54 / 100